Conduct Hit-to-Lead Progression Studies on Interventional Agents: Identification of Anti-HIV Lead Compounds

对介入药物进行从先导化合物到先导化合物的进展研究：抗 HIV 先导化合物的鉴定

• 批准号: 10927005
• 负责人: CORINNE AUGELLI-SZAFRAN
• 金额: $ 40.35万
• 依托单位: SOUTHERN RESEARCH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10927005
• 关键词: Acquired Immunodeficiency Syndrome; Basic Science; Cells; Clinical Trials; Collaborations; Communities; Contracts; Development; Devices; Extramural Activities; Gene Expression; HIV; HIV Infections; Intervention; Investigational New Drug Application; Investigator-Initiated Research; Lead; Licensure; National Institute of Allergy and Infectious Disease; Private Sector; Research; Resources; Services; Therapeutic; United States Food and Drug Administration; Work; novel therapeutics; pre-clinical; product development; research clinical testing; research study

Preclinical Services for HIV Therapeutics: The purpose of these Indefinite Delivery/Indefinite Quantity contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies or from collaborations with private sector or academic partners. The scope of work encompasses activities that range from basic research and initial product discovery to activities required for clinical trials and/or product licensure. These services may also be used to support product discovery and development leading to Investigational New Drug Application (IND), Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID Division of AIDS will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The purpose of this task order is to develop potential compounds with activity to block HIV infection, inhibit HIV gene expression and replication, or cure infected cells of HIV infection.

艾滋病毒治疗的临床前服务：这些不确定交付/不确定数量合同的目的是为外部科学界提供研究材料和临床前产品开发支持，这些候选产品来自研究人员发起的研究研究或与私营部门或学术合作伙伴的合作。工作范围包括从基础研究和初步产品发现到临床试验和/或产品许可所需的活动。这些服务还可以用于支持产品发现和开发，从而导致向食品和药物管理局(FDA)提交调查性新药申请(IND)、研究设备豁免(IDE)和/或新药申请(NDA)。NIAID艾滋病司将主要使用这些合同来更快、更有效地填补关键的开发和资源缺口，并将有前途的产品推向临床测试。这项任务的目的是开发具有阻断艾滋病毒感染、抑制艾滋病毒基因表达和复制、或治愈艾滋病毒感染的受感染细胞的潜在活性化合物。